• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Editas teases tiny sickle cell sample in effort to climb back into gene editing's...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Dec 06, 2022 at 10:42: AM
via Its been a rough and tumble 2022 for Editas Medicine, marked by a new executive team, the suspension of its lead asset and navigating a clinical hold on the efficacy portion of a sickle cell program.

article source
 




Top Bottom
Back
Quote